NT-proBNP blood levels in patients with type 2 diabetes mellitus with anemia and after the dapagliflozin treatment

Authors

  • L.K. Sokolova V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kiev
  • V.M. Pushkarev V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kiev
  • Yu.B. Belchina V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kiev
  • V.V. Pushkarev V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kiev
  • O.V. Furmanova V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kiev
  • S.A. Cherviakova V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kiev
  • O.I. Kovzun V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kiev
  • M.D. Tronko V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kiev

DOI:

https://doi.org/10.15407/dopovidi2018.11.091

Keywords:

AMPK, anemia, dapagliflozin, NT-proBNP, type 2 diabetes

Abstract

The content of the brain natriuretic peptide (NT-proBNP) in blood plasma and the activity of 5′-adenosine monophosphate-activated protein kinase (AMPK) in lymphocytes of type 2 diabetes patients with anemia and after the treatment with dapagliflozin are determined with enzyme immunoassay. It is shown that the highest level of NTproBNP is observed in patients with severe anemia. At the treatment with dapagliflozin, the peptide level was markedly reduced, which may be explained by an increase in the activity of AMPK as a result of the exposure to a hypoglycemic drug. It is suggested that the treatment with dapagliflozin may have a positive effect on complications of type 2 diabetes associated with cardiovascular pathologies.

Downloads

Download data is not yet available.

References

Mahadavan, G., Nguyen, T. H. & Horowitz, J. D. (2014). Brain natriuretic peptide: a biomarker for all cardiac disease? Curr. Opin. Cardiol., 29, No. 2, pp. 160-166. doi: https://doi.org/10.1097/HCO.0000000000000036

Goncalves, G. K., Caldeira de Oliveira, T. H. & de Oliveira Belo, N. (2017). Cardiac hypertrophy and brain natriuretic peptide levels in an ovariectomized rat model fed a high-fat diet. Med. Sci. Monit. Basic Res., No. 23, pp. 380-391. doi: https://doi.org/10.12659/MSMBR.907162

Wolsk, E., Claggett, B., Pfeffer, M. A., Diaz, R., Dickstein, K., Gerstein, H. C., Lawson, F. C., Lewis, E. F., Maggioni, A. P., McMurray, J. J. V., Probstfield, J. L., Riddle, M. C., Solomon, S. D., Tardif, J. C. & Køber, L. (2017). Role of B-type natriuretic peptide and N-terminal prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and type 2 diabetes mellitus. J. Am. Heart. Assoc., 6, No. 6, e004743. doi: https://doi.org/10.1161/JAHA.116.004743

Wu, A. H., Omland, T., Wold Knudsen, C., McCord, J., Nowak, R. M., Hollander, J. E., Duc, P., Storrow, A. B., Abraham, W. T., Clopton, P., Maisel, A. S., McCullough, P.A. & Breathing Not Properly Multinational Study Investigations. (2005). Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) Multinational Study. Am. J. Hematol., 80, No. 3, pp. 174-180. doi: https://doi.org/10.1002/ajh.20456

Antwi-Bafour, S., Hammond, S., Adjei, J. K., Kyeremeh, R., Martin-Odoom, A. & Ekem, I. (2016). A casecontrol study of prevalence of anemia among patients with type 2 diabetes. J. Med. Case Rep., 10, No. 1, pp. 110. doi: https://doi.org/10.1186/s13256-016-0889-4

Chung, J. O., Park, S. Y., Cho, D. H., Chung, D. J. & Chung, M. Y. (2017). Anemia, bilirubin, and cardiovascular autonomic neuropathy in patients with type 2 diabetes. Medicine (Baltimore)., 96, No. 15, e6586. doi: https://doi.org/10.1097/MD.0000000000006586

Filippatos, T. D., Liberopoulos, E. N. & Elisaf, M. S. (2015). Dapagliflozin in patients with type 2 diabetes mellitus. Ther. Adv. Endocrinol. Metab., 6, No. 1, pp. 29-41. doi: https://doi.org/10.1177/2042018814558243

Saha, A. K., Xu, X. J., Balon, T. W., Brandon, A., Kraegen, E. W. & Ruderman, N. B. (2011). Insulin resistance due to nutrient excess. Is it a consequence of AMPK downregulation? Cell Cycle., 10, No. 20, pp. 3447-3451. doi: https://doi.org/10.4161/cc.10.20.17886

Pushkarev, V. M., Sokolova, L. K., Pushkarev, V. V. & Tronko, N. D. (2016). The role of AMPK and mTOR in the development of insulin resistance and type 2 diabetes. The mechanism of metformin action. Probl. Endocrinol. Pathol., No. 3, pp. 77-90 (in Russsian).

Cai, Y., Zhao, L., Qin, Y. & Wu, X. Q. (2015). EGCG blocked phenylephrin-induced hypertrophy in H9C2 cardiomyocytes, by activating AMPK-dependent pathway. Korean J. Physiol. Pharmacol., 19, No. 3, pp. 203-210. doi: https://doi.org/10.4196/kjpp.2015.19.3.203

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., Inzucchi, S. E., & EMPA-REG OUTCOME Investigators. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med., 373, No. 22, pp. 2117-2128. doi: https://doi.org/10.1056/NEJMoa1504720

Downloads

Published

20.05.2024

How to Cite

Sokolova, L., Pushkarev, V., Belchina, Y., Pushkarev, V., Furmanova, O., Cherviakova, S., Kovzun, O., & Tronko, M. (2024). NT-proBNP blood levels in patients with type 2 diabetes mellitus with anemia and after the dapagliflozin treatment . Reports of the National Academy of Sciences of Ukraine, (11), 91–95. https://doi.org/10.15407/dopovidi2018.11.091

Issue

No. 11 (2018): Reports of the National Academy of Sciences of Ukraine

Section

Medicine

License

Copyright (c) 2024 Reports of the National Academy of Sciences of Ukraine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Most read articles by the same author(s)

1 2 > >>